Idorsia sets itself up for failure

Idorsia’s faith in cenerimod might be understandable in the context of lupus recently becoming an area for deal-making interest. But the group’s decision to press on into phase 3 trials after cenerimod today flopped in phase 2 seems reckless, and potentially sets the project up for an even bigger failure later on.